Skip to main content
INCY logo

Incyte Corporation (INCY) Stock: Price, Forecast & Analyst Target

Incyte Corporation (INCY) — MoonshotScore 91/100 (Exceptional band), calculated Nov 18, 2026. Price $117.80 (-1.08%), as of the Nov 18, 2026 trading session; market cap $24.0B. Expected results Feb 9, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$117.80 −$1.29 (-1.08%) Market Cap $24.0B

Incyte Corporation · INCY · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: Incyte is a commercial biopharmaceutical company whose marketed therapies already generate substantial profit and cash, rather than a development-stage business dependent on outside funding. The durability question is whether the Jakafi franchise can finance expansion through Opzelura and the pipeline before the forecast revenue path turns lower.

Price as of Nov 18, 2026

Key Statistics

91 of 100

MoonshotScore v2 · Incyte (INCY)

Exceptional
Business Quality Elite (90)
Financial Safety Fortress (95)
Valuation Full (49)
Growth Durability Growing (63)
Momentum Surging (82)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and a fortress balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 6 of the last 8 reports
  • expected results Feb 9, 2027
  • Altman Z 10.78 · Piotroski F 6

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for INCY (57 recorded, newest six shown)
RecordedScoreBand
88Exceptional
96Exceptional
96Exceptional
96Exceptional
91Exceptional
91Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$117.80
Change on the day-1.08%
52-week range$89.25–$132.60
Market capitalisation$24.0B—
Price / earnings (trailing)56.71
Shares traded on the day1.21M
Beta (volatility vs the S&P 500)0.78

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $88, high $128, latest $118. $128 $88 high $128 Oct 17, 2025 Nov 18, 2026 · $118 $88Oct 17, 2025$93Oct 31, 2025$104Nov 14, 2025$104Nov 28, 2025$95Dec 12, 2025$100Dec 26, 2025$107Jan 9, 2026$102Jan 23, 2026$108Feb 6, 2026$101Feb 20, 2026$96Mar 6, 2026$91Mar 20, 2026$96Apr 2, 2026$98Apr 17, 2026$97May 1, 2026$95May 15, 2026$97May 29, 2026$109Jun 12, 2026$114Jun 26, 2026$117Jul 10, 2026$118Jul 24, 2026$121Aug 7, 2026$128Aug 21, 2026$127Sep 4, 2026$125Sep 18, 2026$115Oct 2, 2026$113Oct 16, 2026$120Oct 30, 2026$121Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Incyte (INCY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Strong
Debt/Equity Strong
ROE Neutral
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Incyte (INCY), and what does it report?

Short answer · as of

Incyte researches, develops and markets therapies led by Jakafi, with Opzelura, Minjuvi and partnered economics adding other revenue streams.

Jakafi treats blood disorders, while the broader portfolio and pipeline span additional cancers and immune-related conditions.

Reported revenue is not solely sales from owned medicines: it also includes royalties, milestones and contract revenue. Jakafi supplies most of the disclosed segment revenue, making prescription demand for that franchise far more consequential than the biotechnology label alone suggests.

2 · Latest results

What do the latest results show for Incyte (INCY)?

Recent results accelerated from the preceding period: revenue, operating profit, net income and diluted earnings all rose sharply, while the latest release cleared consensus on revenue and earnings. The annual record also shows revenue reaching a new high and profit recovering strongly after a year of unusually heavy research spending.

The disclosed annual mix keeps that improvement anchored to Jakafi, with Opzelura meaningful but still much smaller. Management says expected Jakafi XR sales are already included in full-year Jakafi guidance, while additional-country launches and reimbursement expansion should produce modest initial revenue followed by stronger momentum.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$1.37B$424M$2.11 (diluted)
Q4 FY2025$1.51B$299M$1.46 (diluted)
Q1 FY2026$1.27B$303M$1.47 (diluted)
Q2 FY2026$1.67B$586M$2.81 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Incyte (INCY)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Incyte combines recurring operating cash generation with a cash and investment balance that greatly exceeds debt and total liabilities. Liquidity has climbed steadily across the reported history, while capital expenditure has remained modest relative to operating cash flow.

That financial capacity supports a research program whose spending can materially change reported profit. The business risk is concentration: if Jakafi weakens before Opzelura and pipeline assets close the gap, the cash cushion can absorb investment but cannot preserve the revenue base by itself.

4 · What to check next?

What should you watch next at Incyte (INCY)?

Short answer · as of

The next earnings report is expected on Feb 9, 2027.

The scheduled earnings release carries a consensus loss after a sustained run of profitable periods, despite an expected revenue level that remains substantial. Watch research and commercial spending, operating cash conversion and whether liquidity continues to build through that earnings reset.

Product mix matters beyond the immediate release. Jakafi XR execution, Opzelura’s contribution and reimbursement-supported launches need to broaden the commercial base before longer-range estimates reach their expected revenue retreat; the widening spread among those estimates signals increasing uncertainty around that transition.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Incyte compare with its peers?

Short answer

Incyte's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with development-stage biotechnology businesses, Incyte already funds research from a profitable commercial franchise and recurring operating cash flow. Compared with diversified pharmaceutical companies, its revenue base remains unusually dependent on Jakafi, with Opzelura smaller and royalties, milestones and contract revenue ancillary.

That combination creates unusual financial autonomy alongside pronounced product concentration. The balance sheet gives Incyte room to develop and commercialize additional therapies, but diversification must come from assets already connected to its research and commercial system rather than from leverage.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Named competitor$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte (INCY) — this page$117.80$24.0B91
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$104.00 – $157.00
Consensus target
$136.47
Median target
$140.00

Consensus record · Captured .

Measured against a quoted price of $117.80 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
100
Identified insiders
10
Purchases
0
Sales
26
Other transactions
74

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held INCY in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.11%$24.73MAdded +21.1% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Incyte (INCY)?

Read these with our analysis →

What Investors Ask About Incyte (INCY) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Jakafi so important to Incyte?

Jakafi contributes most of Incyte’s disclosed segment revenue and therefore carries disproportionate influence over growth, profit and the funding available for research. Opzelura and partnered revenue broaden the mix, but they remain much smaller.

How does Opzelura change Incyte’s revenue mix?

Opzelura is the largest disclosed revenue source outside Jakafi, giving Incyte another owned commercial product with meaningful scale. Its current contribution broadens the portfolio without yet removing Jakafi concentration.

Can Jakafi cash generation fund Incyte’s pipeline without debt?

Operating cash flow has remained positive, liquidity has risen steadily and debt is minimal beside cash and investments. That position supports heavy research spending without making borrowing central to the current funding model.

What is management expecting from Jakafi XR?

Management expects Jakafi XR to contribute meaningful sales and has already incorporated that contribution into full-year Jakafi guidance. Delivery therefore supports the existing outlook rather than representing upside outside it.

What is the INCY stock price today?

The last price recorded for Incyte Corporation (INCY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the INCY price target?

The analyst consensus price target for Incyte Corporation (INCY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Analyst revenue and earnings estimates (average)
  • 1. What is Incyte (INCY), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Incyte (INCY)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Revenue by segment; Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Incyte (INCY)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Revenue by segment
  • 4. What should you watch next at Incyte (INCY)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Revenue by segment; Management outlook — dated call excerpts; Analyst revenue and earnings estimates (average)
  • 5. How does Incyte compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value
  • FAQ: Why is Jakafi so important to Incyte?: Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • FAQ: How does Opzelura change Incyte’s revenue mix?: Revenue by segment; Business description
  • FAQ: Can Jakafi cash generation fund Incyte’s pipeline without debt?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Annual revenue and net result (USD millions)
  • FAQ: What is management expecting from Jakafi XR?: Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.